Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic ReviewFunding None.
04 August 2017 (eFirst)
Background To date, the exact prevalence of anti-β2 glycoprotein I domain I (anti-β2GPI-DI) antibodies in patients with antiphospholipid syndrome (APS) and their role when assessing thrombosis risk is uncertain.
Objectives To estimate the prevalence of anti-β2GPI-DI in patients with APS and to determine whether anti-β2GPI-DI-positive individuals are at greater risk of thrombosis, as compared with individuals without anti-β2GPI-DI, by systematically reviewing the literature.
Methods A detailed literature search was applied a priori to Ovid MEDLINE In-Process and Other Non-Indexed Citation 1986 to present and to abstracts from the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP ) Annual Meetings (2011–2015).
Results A total of 11 studies, including 1,585 patients, were analyzed. Patients were distributed as follow: 1,218 patients APS (45.4% anti-β2GPI-DI-positive; in more detail: 504 primary APS [55.4% anti-β2GPI-DI-positive], 192 secondary APS [43.2% anti-β2GPI-DI-positive], and 522 not specified), 318 with systemic lupus erythematosus (SLE; 26.7% anti-β2GPI-DI-positive), 49 asymptomatic carriers of antiphospholipid antibodies (aPL) (30.6% anti-β2GPI-DI-positive), and 1,859 healthy controls. When considering the five studies eligible for thrombotic risk assessment, four studies found a significant association of anti-β2GPI-DI-positivity with thrombotic events, whereas one study found no predictive correlation with thrombosis (overall odds ratio [OR] for pooled data: 1.99; 95% confidence interval [CI]: 1.52–2.6; p < 0.0001).
Conclusion We report an overall estimated median prevalence of anti-β2GPI-DI antibodies of 44.3% in patients with APS and/or SLE and a significantly higher prevalence among patients with APS compared with SLE alone. Anti-β2GPI-DI antibodies might represent a promising tool when assessing thrombotic risk in patients with APS.
Keywordsantiphospholipid syndrome - antiphospholipid antibodies - β2 glycoprotein I domain - non-criteria aPL - thrombosis
M.R. and I.C. searched the literature, assisted with the organization of the manuscript, interpreted and collected data, and wrote and edited the review. P.L.M., D.R., and S.S. interpreted and collected data, helped to design the figures and panel, and wrote and edited the review.
- 1 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
- 2 Meroni PL. Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools. Lupus 2016; 25 (08) 905-910
- 3 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7 (06) 330-339
- 4 Raschi E, Chighizola CB, Grossi C. , et al. β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 2014; 55: 42-50
- 5 Filippidou N, Krashias G, Pericleous C. , et al. The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. Mol Immunol 2016; 75: 161-167
- 6 Ambrozic A, Avicin T, Ichikawa K. , et al. Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol 2002; 14 (07) 823-830
- 7 Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012; 12 (02) 313-317
- 8 Pengo V, Ruffatti A, Tonello M. , et al. Antibodies to domain 4/5 (Dm4/5) of β2-glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res 2015; 136 (01) 161-163
- 9 de Laat B, Pengo V, Pabinger I. , et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7 (11) 1767-1773
- 10 Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95 (26) 15542-15546
- 11 de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011; 13 (01) 70-76
- 12 Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-β 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 2000; 15 (02) 91-96
- 13 Pericleous C, Ferreira I, Borghi O. , et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One 2016; 11 (06) e0156407
- 14 Ioannou Y, Romay-Penabad Z, Pericleous C. , et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009; 7 (05) 833-842
- 15 Agostinis C, Durigutto P, Sblattero D. , et al. A noncomplement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014; 123 (22) 3478-3487
- 16 Sciascia S, Baldovino S, Schreiber K. , et al. Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clin Mol Allergy 2016; 14 (01) 6
- 17 Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011; 9 (01) 1
- 18 PRISMA 2009 checklist. Available at: http://prisma-statement.org/documents/PRISMA%202009%20checklist.pdf . Accessed: December 2016
- 19 Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed: December 2016
- 20 Andreoli L, Nalli C, Motta M. , et al. Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile?. Ann Rheum Dis 2011; 70 (02) 380-383
- 21 Müller-Calleja N, Rossmann H, Müller C. , et al. Antiphospholipid antibodies in a large population-based cohort: genome-wide associations and effects on monocyte gene expression. Thromb Haemost 2016; 116 (01) 115-123
- 22 Pengo V, Ruffatti A, Tonello M. , et al. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015; 13 (05) 782-787
- 23 Willis R, Pierangeli SS. Anti-β2-glycoprotein I antibodies. Ann N Y Acad Sci 2013; 1285 (01) 44-58
- 24 Despierres L, Beziane A, Kaplanski G. , et al. Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. Rheumatology (Oxford) 2014; 53 (07) 1215-1218
- 25 Andreoli L, Nalli C, Borghi MO, Pregnolato F, Grossi C, Zangola A. , et al. Domain I is the main specificity of anti-beta2 GPI in systemic autoimmune diseases. Arthritis Rheum 2013; 65: S4
- 26 Zohoury N, Khamashta MA, Atsumi T, Musial J, Watanabe T, Papp M. , et al. Autoantibodies targeting domain 1 of beta 2 glycoprotein I as promising marker in the diagnosis and risk stratification of the antiphospholipid syndrome. Arthritis Rheum 2013; S4: 10
- 27 de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109 (04) 1490-1494
- 28 Manukyan D, Rossmann H, Schulz A. , et al. Distribution of antiphospholipid antibodies in a large population-based German cohort. Clin Chem Lab Med 2016; 54 (10) 1663-1670
- 29 Roggenbuck D, Borghi MO, Somma V. , et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther 2016; 18 (01) 111
- 30 Rodríguez-García V, Ioannou Y, Fernández-Nebro A, Isenberg DA, Giles IP. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology (Oxford) 2015; 54 (11) 2042-2050
- 31 Meneghel L, Ruffatti A, Gavasso S. , et al. Detection of IgG anti-domain I beta2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta 2015; 446: 201-205
- 32 de Laat B, Derksen RHWM, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105 (04) 1540-1545
- 33 Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102 (08) 2717-2723
- 34 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (05) 1827-1832
- 35 Zhang S, Wu Z, Chen S. , et al. Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Sci Rep 2016; 6 (01) 23839
- 36 Agmon-levin N, Seguro L, Rosa C. , et al. Anti-β2GPI-D1 antibodies are a marker of APS severity. Arthritis Rheumatol 2013; 65 (10) S4
- 37 Wahezi DM, Ilowite NT, Wu XX. , et al; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus 2013; 22 (07) 702-711
- 38 Mahler M, Albesa R, Zohoury N. , et al. Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus 2016; 25 (08) 911-916
- 39 Cieśla M, Wypasek E, Undas A. IgA antiphospholipid antibodies and anti-domain 1 of Beta 2 glycoprotein 1 antibodies are associated with livedo reticularis and heart valve disease in antiphospholipid syndrome. Adv Clin Exp Med 2014; 23 (05) 729-733
- 40 Mondejar R, González-Rodríguez C, Toyos-Sáenz de Miera FJ. , et al. Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 2014; 431: 174-178
- 41 Hunt BJ, Wu X-X, de Laat B, Arslan AA, Stuart-Smith S, Rand JH. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol 2011; 205 (05) 485.e17-485.e23
- 42 Andreoli L, Chighizola CB, Nalli C. , et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 2015; 67 (08) 2196-2204
- 43 De Craemer A-S, Devreese KM. Role of anti-domain 1-ß2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome: reply. J Thromb Haemost 2016; 14 (10) 2078-2080
- 44 Cousins L, Pericleous C, Khamashta M. , et al. Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome. Ann Rheum Dis 2015; 74 (01) 317-319
- 45 Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014; 16 (02) 402
- 46 Willis R, Grossi C, Orietta Borghi M. , et al. International standards for IgG and IgM anti-β2glycoprotein antibody measurement. Lupus 2014; 23 (12) 1317-1319
- 47 Conrad K, Andrade LE, Chan EK, Mahler M, Meroni PL, Pruijn GJ. , et al. From autoantibody research to standardized diagnostic assays in the management of human diseases - . Report of the 12th Dresden Symposium on Autoantibodies. Lupus 2016; 25 (08) 787-796